ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 0319 • ACR Convergence 2022

    Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy

    Daming Shao1, Alejandra Londoño Jimenez2, Maria Auxiliadora Salgado Guerrero3, Anna Broder4 and Shudan Wang5, 1Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, 2McFarland Clinic, Ames, IA, 3University of Alabama at Birmingham, Birmingham, AL, 4Hackensack University Medical Center, Hackensack, NJ, 5Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Approximately 10 to 30% of patients with LN progress…
  • Abstract Number: 0539 • ACR Convergence 2022

    Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use

    Anna Broder1, Wenzhu B. Mowrey2, Kazuki Yoshida3 and Karen Costenbader3, 1Hackensack University Medical Center, Hackensack, NJ, 2Albert Einstein College of Medicine, Bronx, NY, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Medication management strategies in patients with lupus-related end stage kidney disease (ESKD) have not been studied. Our prior work has shown that HCQ may…
  • Abstract Number: 0986 • ACR Convergence 2022

    Impact of Weight and Race on Renal Response to Cyclophosphamide in the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS)

    Julia Ford, William McCune, Neil Kamdar and Michael O'Leary, University of Michigan, Ann Arbor, MI

    Background/Purpose: ACCESS assessed the efficacy of abatacept (ABA) as induction therapy in lupus nephritis (LN), randomizing 134 patients to ABA vs. placebo on a background…
  • Abstract Number: 1467 • ACR Convergence 2022

    Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience

    Savino Sciascia1, Alice Barinotti2, Massimo Radin2, Irene Cecchi1, Elisa Menegatti2, Vittorio Modena2, Daniela Rossi2, Simone Baldovino2, Roberta Fenoglio2 and Dario Roccatello2, 1University of Turin, Torino, Italy, 2University of Turin, Turin, Italy

    Background/Purpose: Lupus Nephritis (LN) is a major cause of mortality/morbidity in patients affected by Systemic Lupus Erythematosus (SLE). Reliable prognostic markers, especially related to the…
  • Abstract Number: 2065 • ACR Convergence 2022

    Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares

    Diane Zisa1, Jeffrey Zhang-Sun1, Paul Christos2 and Kyriakos Kirou1, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine/New York-Presbyterian, New York, NY

    Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…
  • Abstract Number: 0531 • ACR Convergence 2021

    Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics

    Asmaa AbuMaziad1, Abhimanyu Amarnani2 and Ram Singh3, 1University of California Los Angeles, Los Angeles, CA, 2Los Angeles County + University of Southern California, Los Angeles, CA, 3University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…
  • Abstract Number: 1291 • ACR Convergence 2021

    Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus

    Eun Song Kang1, Ji Seon Oh2, Soo Min Ahn1, Yong Gil Kim1, Chang-Keun Lee1, Bin Yoo3 and Seokchan Hong3, 1Asan Medical Center, Seoul, Republic of Korea, 2Asan Medical Center, Ulsan, Republic of Korea, 3Asan Medical Center, Seoul, South Korea

    Background/Purpose: Kidney biopsy is essential for the diagnosis and classification of lupus nephritis in patients with systemic lupus erythematosus (SLE). Even though the risk of…
  • Abstract Number: 1749 • ACR Convergence 2021

    Treatment Patterns in Latin American Patients with Lupus Nephritis over a 20-year Period

    Rosana quintana1, Jose Gomez Puerta2, Guillermina Harvey3, Marina Scolnik4, Nidia Meras5, Cintia Otaduy6, Maria Salinas7, Valeria Arturi8, Maria Sattler9, Rosa Serrano Morales1, Luciana Gonzalez Lucero10, Wilfredo Grageda11, Nicolas Perez12, Cecilia Nora Pisoni13, Simone Appenzeller14, Ana Silva15, Odirlei Andre Monticielo16, Henrique Moriz17, Francinne Ribiero18, Emily Figueiredo Neves Yuki Yuki19, Edgard Neto20, Iris Guerra21, Paula Burgos22, Milena Mimica23, Gustavo Aroca24, Gabriel Tobon25, Luis Gonzalez26, Gerardo Quintana-López27, Andres Bonfanti24, RAFAEL LOPEZ28, Luis Jara Quezada29, Margarita Portela-Hernandez30, HILDA FRAGOSO LOYO31, Luis H Silveira32, Ignacio Garcia-De La Torre33, Carlos Abud-Mendoza34, Jorge Esquivel-Valerio35, Jonathan Losanto36, Astrid Paats37, JORGE CIEZA CALDERON38, Manuel Ugarte-Gil39, Katiuzka Zuniga Corrales40, Roberto Munoz41, Ernesto Cairoli42, Gonzalo Silveira43, Luis Catoggio44, Ashley Orillion45, Chetan Karyekar46, Federico Zazzetti47 and Bernardo A. Pons-Estel48, 1Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina, 2Hospital Clinic, University of Barcelona, Barcelona, Spain, 3Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, 4Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Hospital Italiano de Córdoba, Córdoba, Argentina, 6Hospital Córdoba, Cordoba, Argentina, 7Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 8Hospital HIGA San Martín, La Plata, Argentina, 9Sanatorio Británico, Cordoba, Argentina, 10Janssen Cilag Farmaceutica SA, Tucuman, Argentina, 11Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, 12Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, 13CEMIC, Buenos Aires, Argentina, 14Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, 15UFG, GOIANIA, Goias, Brazil, 16Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 17Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, 18Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, 19Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, 20UNIFESP, São Paulo, Brazil, 21Hospital del Salvador, Santiago, Chile, 22Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, 23Universidad San Sebastián, Santiago, Chile, 24Clínica de la Costa Ltda., Barranquilla, Colombia, 25Fundación Valle del Lili, Cali, Colombia, 26Universidad de Antioquia, Medellin, Colombia, 27Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, 28Hospital Luis Vernaza, Guayaquil, Ecuador, 29Centro Médico La Raza, Mexico City DF, Mexico, 30IMSS, Mexico Df, Mexico, 31INCMNSZ, Tlalpan, Mexico, 32Instituto Nacional de Cardiologia, Mexico City, Mexico, 33Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, 34Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 35University Hospital Dr. Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 36Hospital de Clínicas I, San Lorenzo, Paraguay, 37Hospital de Clinicas, Asuncion, Paraguay, 38Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, 39Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 40Hospital Cayetano Heredia, Lima, Peru, 41Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, 42Autoimmune Diseases Unit, Centro Asistencial del Sindicato Médico del Uruguay (CASMU) and Hospital Evangélico, Montevideo, Uruguay, 43Hospital Señor del Milagro, Salta, Argentina, 44Hospital Italiano de Buenos Aires, Olivos, Argentina, 45Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, 46Janssen R&D, Spring House, PA, 47Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, 48Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. Over the last decade, changes have occurred in the treatment of these patients,…
  • Abstract Number: 0535 • ACR Convergence 2021

    Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)

    Priyal Dave1, Tiange Dong1, Andrew Mead1, Isaac Asante1, Brandon Ebright1, Eugene Zhou1, RIta Li1, Nicos Petasis1, William Stohl2 and Stan Louie1, 1University of Southern California, Los Angeles, CA, 2University of Southern California Keck School of Medicine, Los Angeles, CA

    Background/Purpose: Neutrophils are key initiators and promoters of autoimmunity, including SLE, via the elaboration of neutrophil extracellular traps (NETs). We tested the efficacy of the…
  • Abstract Number: 1299 • ACR Convergence 2021

    Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network

    Peter Izmirly1, Maria Dall'Era2, Kenneth Kalunian3, Kristina Deonaraine1, Mimi Kim4, Philip Carlucci1, Jessica Li5, Andrea Fava5, H. Michael Belmont6, Chaim Putterman7, Jennifer Anolik8, Betty Diamond9, David Wofsy10, Diane Kamen11, Judith James12, Accelerating Medicines Partership (AMP) RA/SLE Network13, Deepak Rao14, The Accelerating Medicines Partnership in SLE Network15, Michelle Petri16, Jill Buyon6 and Richard Furie17, 1New York University School of Medicine, New York, NY, 2University of California San Francisco, Corte Madera, CA, 3UC San Diego, La Jolla, CA, 4Albert Einstein College of Medicine, Larchmont, NY, 5Johns Hopkins University, Baltimore, MD, 6NYU School of Medicine, New York, NY, 7Albert Einstein College of Medicine, Bronx, NY, 8University of Rochester Medical Center, Rochester, NY, 9Northwell Health, Manhasset, NY, 10University of California San Francisco, San Francisco, CA, 11Medical University of South Carolina, Charleston, SC, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13Brigham and Women's Hospital, Everett, MA, 14Brigham and Women's Hospital, Boston, MA, 15Multiple Institutions, Multiple Cities, 16Johns Hopkins University School of Medicine, Baltimore, MD, 17Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY

    Background/Purpose: The Accelerating Medicines Partnership (AMP) Lupus Network was established with the goal of applying novel technologies to the interrogation of blood and tissue samples…
  • Abstract Number: 1750 • ACR Convergence 2021

    Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study

    Kenneth Kalunian1, Richard Furie2, Jai Radhakrishnan3, Vandana Mathur4, Krishna Polu4, Stephen Connelly4, Joel Rothman4, Cherie Ng4, Leslie Chinn5, Maple Fung6, Dolca Thomas7 and Chaim Putterman8, 1UC San Diego, La Jolla, CA, 2Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 3Columbia University, New York, NY, 4Equillium, Inc., La Jolla, CA, 5Equillium, Inc., South San Francisco, CA, 6Equillium, Inc., San Diego, CA, 7Equillium, Inc., Brooklyn, NY, 8Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: CD6, a co-stimulatory receptor predominantly expressed on T cells, promotes CD4+ T cell proliferation and differentiation into Th1/Th17 cells. The CD6 ligand, activated leukocyte…
  • Abstract Number: 0077 • ACR Convergence 2021

    Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus

    Prarthana Jain, Jim Oates, Dulaney Wilson and Diane Kamen, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Antiphospholipid antibody (aPL) positivity is associated with elevated risk of thrombosis among patients with SLE, but other clinical associations are less well-known. The goal…
  • Abstract Number: 0538 • ACR Convergence 2021

    Strengthening Nuclear Envelope Ameliorates UVB-triggered Skin Inflammation and Kidney Damage in Lupus Mice

    Xing Lyu1, Minghui Li2, Ping L Zhang3, Victoria Werth4 and Ming-Lin Liu4, 1Tianjin Medical University General Hospital, Philadelphia, PA, 2Tianjin Medical University General Hospital, Tianjin, China (People's Republic), 3Division of Anatomic Pathology,Beaumont Laboratories, Beaumont Health, Royal Oak, MI, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Ultraviolet B (UVB) exposure triggers lupus flare by worsening skin lesions and systemic symptoms such as lupus nephritis. The effects of UVB-induced skin inflammation…
  • Abstract Number: 1422 • ACR Convergence 2021

    Urinary CD163 Predicts Proliferative Lupus Nephritis in SLE Patients with Proteinuria: A Practical Liquid Biopsy Approach

    Andrea Fava1, Jessica Li1, Daniel Goldman2, Jose Monroy-Trujillo1, Mohamed G. Atta1, Derek Fine1, Jill Buyon3, Joel Guthridge4, Judith James4, Michelle Petri2 and Accelerating Medicines Partership (AMP) RA/SLE Network5, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3NYU School of Medicine, New York, NY, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Brigham and Women's Hospital, Everett, MA

    Background/Purpose: Diagnosis of lupus nephritis (LN) relies on a kidney biopsy obtained in SLE with proteinuria. Delayed access to kidney biopsies may delay diagnosis and…
  • Abstract Number: 1751 • ACR Convergence 2021

    Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

    Anca Askanase1, Simrat Randhawa2, Laura Lisk3 and Paola Mina-Osorio4, 1Columbia University Medical Center, New York, NY, 2Aurinia Pharmaceuticals Inc., Seattle, WA, 3Aurinia Pharmaceuticals Inc., Victoria, ON, Canada, 4Aurinia Pharmaceuticals Inc., New York, NY

    Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adult patients with active lupus nephritis in combination with background immunosuppressive therapy.…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology